Shinpoong Pharmaceutical

019170 · KOSPI · Health Care · SMALL CAP

Updated terms.

Shinpoong Pharmaceutical updated the disclosed terms of an acquisition of Hyundai Pharmaceutical, now worth US$20.6M.

M&A([Amended] Decision to acquire shares/equity in another company)· FILED 2026-02-27· RCEPT 20260227802140

US$20.6MDeal value
8.6%vs. company assets

Converted at 1 USD ≈ ₩1,432.32 (filing-date rate, 2026-02-27 close)

What happened

Shinpoong Pharmaceutical updated the disclosed terms of an acquisition of Hyundai Pharmaceutical, now worth US$20.6M.

For context, this deal is worth about 8.6% of the company's own total assets.

TargetHyundai Pharmaceutical
Deal valueUS$20.6M
vs. company assets8.6%
Filed2026-02-27, [Amended] Decision to acquire shares/equity in another company
SourceDART rcept 20260227802140 → open original filing

Versions of this filing

  1. 2026-02-26Original
  2. 2026-02-27Amendment 1 (this page)

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-02-27 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.